Asset Details
Do you wish to reserve the book?
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
Do you wish to request the book?
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Interim analyses of a first-in-human phase 1/2 mRNA trial for propionic acidaemia
2024
Overview
Propionic acidaemia is a rare disorder caused by defects in the propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits that leads to an accumulation of toxic metabolites and to recurrent, life-threatening metabolic decompensation events. Here we report interim analyses of a first-in-human, phase 1/2, open-label, dose-optimization study and an extension study evaluating the safety and efficacy of mRNA-3927, a dual mRNA therapy encoding PCCA and PCCB. As of 31 May 2023, 16 participants were enrolled across 5 dose cohorts. Twelve of the 16 participants completed the dose-optimization study and enrolled in the extension study. A total of 346 intravenous doses of mRNA-3927 were administered over a total of 15.69 person-years of treatment. No dose-limiting toxicities occurred. Treatment-emergent adverse events were reported in 15 out of the 16 (93.8%) participants. Preliminary analysis suggests an increase in the exposure to mRNA-3927 with dose escalation, and a 70% reduction in the risk of metabolic decompensation events among 8 participants who reported them in the 12-month pretreatment period.
Interim data from a clinical trial of mRNA-3927—an mRNA therapeutic for propionic acidaemia—provide early indications of the safety and efficacy of the treatment, and suggest that this approach might be applicable to other rare diseases.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 38/1
/ 45/71
/ 45/90
/ 49/47
/ 692/308
/ 692/699
/ Adult
/ Child
/ Dose-Response Relationship, Drug
/ Enzymes
/ Female
/ Humanities and Social Sciences
/ Humans
/ Infant
/ Male
/ mRNA
/ Propionic Acidemia - genetics
/ Propionic Acidemia - therapy
/ Propionyl-Coenzyme A Carboxylase - genetics
/ Propionyl-Coenzyme A Carboxylase - metabolism
/ RNA, Messenger - administration & dosage
/ RNA, Messenger - adverse effects
/ RNA, Messenger - therapeutic use
/ Science
